Behring CSL acquired Calimmune for an average 8x return. Calimmune assembled a world-class team of researchers, clinicians, and translational experts in related fields of science and medicine to develop innovative cell-based therapies for HIV. The company was formed around stem cell technology discovered in the labs of Nobel Laureate, Dr. David Baltimore (Caltech) and Dr. Irvin Chen (UCLA AIDS Institute) in early 2000.

Learn More